Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2007-09-18
2007-09-18
Falk, Anne-Marie (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S022000
Reexamination Certificate
active
10409672
ABSTRACT:
The present invention is directed to recombinantly engineered mice that are deficient in the expression of both presenilin-1 and presenilin-2. The mice exhibit characteristics of age-dependent cognitive impairments and neurodegeneration similar to those seen in Alzheimer's disease patients. This presenilin-deficient mouse model can be used to screen compounds capable of slowing, preventing or reversing the progression of cognitive impairments and neurodegeneration. The invention is also directed to the development of treatments for Alzheimer's disease based on augmentation or restoration of presenilin function in the brain. On the basis of the findings described herein, the invention is further directed to the development of assays to detect functional presenilin deficiency in human individuals, preferably through analysis of presenilin substrates, which may provide biomarkers useful in the diagnosis of Alzheimer's disease.
REFERENCES:
patent: 4959317 (1990-09-01), Sauer
Doetschman, T. (1999) Interpretation of phenotype in genetically engineered mice. Laboratory Animal Science 49(2): 137-143.
Donehower et al. (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. Molecular Carcinogenesis 14: 16-22.
Jacks et al. (1992) Effects of an Rb mutation in the mouse. Nature 359: 295-300.
Jaenisch et al. (1988) Transgenic Animals. Science 240: 1468-1474.
Kuehn et al. (1987) A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 326: 295-298.
Moens et al. (1993) Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus. Development 119: 485-499.
Petridou et al. (2003) Heterogeneous inducible mammary-specific expression of JAB/SOCS1 in lactating transgenic mice is associated with no obvious phenotype, even at the cellular level. Transgenic Research 12: 693-706.
Sigmund, CD (2000) Viewpoint: Are studies in genetically altered mice out of control? Arterioscler. Thromb. Vasc. Biol. 20: 1425-1429.
Reece, RJ (2004) in Analysis of Genes and Genomes. John Wiley & Sons: Hoboken, New Jersey, p. 388, 389-440.
Bear, “Homosynaptic Long-Term Depression: A Mechanism for Memory?,”Proc. Natl. Acad. Sci. USA 96:9457-9458 (1999).
Borchelt, et al., “Familial Alzheimer's Disease-Linked Presenilin 1 Variants Elevate Aβ1-42/1-40 Ratio In Vitro and In Vivo,”Neuron 17:1005-1013 (1996).
Brun, et al., “Regional Pattern of Degeneration in Alzheimer's Disease: Neuronal Loss and Histopathological Grading,”Histopathology 5: 549-564 (1981).
Crook, et al., “A Variant of Alzheimer's Disease with Spastic Paraparesis and Unusual Plaques Due to Deletion of Exon 9 of Presenelin 1,”Nature Medicine 4:452-455 (1998).
De Jonghe, et al., “Aberrant Splicing in the Presenilin-1 Intron 4 Mutation Causes Presenile Alzheimer's Disease by Increased Aβ42 Secretion,”Hum. Mol. Gen. 8:1529-1540 (1999).
Donoviel, et al., “Mice Lacking Both Presenelin Genes Exhibit Early Embryonic Patterning Defects,”Genes&Dev. 13:2801-2810 (1999).
Duff, et al., “Increased Amyloid-β42(43) in Brains of Mice Expressing Mutant Presenelin 1,”Nature 383:710-713 (1996).
Elbashir, et al., “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes&Dev. 15:188-200 (2001).
Elbashir, et al., “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature 411:494-498 (2001).
Gómez-Isla, et al., “Neuronal Loss Correlates with but Exceeds Neurofibrillary Tangles in Alzheimer's Disease,”Ann. Neurol. 41:17-24 (1997).
Hanks, et al., “Region-Specific Stability of Dendritic Extent in Normal Human Aging and Regression in Alzheimer's Disease. I. CA1 of Hippocampus,”Brain Res. 540:63-82 (1991).
Herreman, et al., “Total Inactivation of γ-Secretase Activity in Presenilin-Deficient Embryonic Stem Cells,”Nature Cell Biology 2:461-462 (2000).
Herreman, et al., “Presenilin 2 Deficiency Causes A Mild Pulmonary Phenotype and No Changes in Amyloid Precursor Protein Processing but Enhances the Embryonic Lethal Phenotype of Presenilin 1 Deficiency,”Proc. Natl. Acad. Sci. USA 96:11872-11877 (1999).
Hiltunen, et al., “Identification of a Novel 4.6-kb Genomic Deletion in Presenilin-1 Gene Which Results in Exclusion of Exon 9 in a Finnish Early Onset Alzheimer's Disease Family: anAluCore Sequence-Stimulated Recombination?,”Eur. J. Hum. Gen. 8:259-266 (2000).
Hyman, et al., “Amyloid, Dementia and Alzheimer's Disease,”Curr. Opin. Neurol. Neurosurg. 5:88-93 (1992).
Jo, et al., “Epigenetic Regulation of Gene Structure and Function with a Cell-Permeable Cre Recombinase,”Nat. Biotechnol. 19:929-933 (2001).
Levy-Lehad, et al., “A Familial Alzheimer's Disease Locus on Chromosome 1,”Science 269:970-973 (1995).
Li, et al., “Photoactivated γ-Secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1,”Nature 405:689-694 (2000).
Rogaev, et al., “Familial Alzheimer's Disease in Kindreds with Missense Mutations in a Gene on Chromosome 1 Related to the Alzheimer's Disease Type 3 Gene,”Nature 376:775-778 (1995).
Scheuner, et al., Secreted Amyloid β-Protein Similar to that in the Senile Plaques of Alzheimer's Disease Is Increased in vivo by the Presenilin 1 and 2 and APP mutations Lined to Familial Alzheimer's Disease,Nature Med. 2:864-870 (1996).
Shen, et al., “Skeletal and CNS Defects in Presenilin-1-Deficient Mice,”Cell 89:629-639 (1997).
Sherrington, et al., “Cloning of a Gene Bearing Missense Mutations in Early-Onset Familial Alzheimer's Disease,”Nature 375:754-760 (1995).
Steiner, et al., “A Loss of Function Mutatioin of Presenilin-2 Interferes with Amyloid β-Peptide Production and Notch Signaling,”J. Biol. Chem. 274:28669-28673 (1999).
Terry, et al., “Physical Basis of Cognitive Alterations in Alzheimer's Disease: Synapse Loss Is the Major Correlate of Cognitive Impairment,”Ann. Neurol. 30:572-580 (1991).
Tysoe, et al., “A Presenilin-1 Truncating Muation Is Present in Two Cases with Autopsy-Confirmed Early-Onset Alzheimer Disease,”Am. J. Hum. Genet. 62:70-76 (1998).
Wilson, et al., “Presenilins Are Not Required for Aβ42 Production in the Early Secretory Pathway,”Nat. Neurosci. 5:849-855 (2002).
Wolfe, et al., “Two Transmembrane Aspartates in Presenilin-1 Required for Presenilin Endoproteolysis and γ-Secretase Activity,”Nature 398:513-517 (1999).
Yoo, et al., “Presenilin-Mediated Modulation of Capacitative Calcium Entry,”Neuron 27:561-572 (2000).
Yu, et al., “APP Processing and Synaptic Plasticity in Presenilin-1 Conditional Knockout Mice,”Neuron 31:713-726 (2001).
Yu, et al., “Heterogeneous Populations of ES Cells in the Generation of a Floxed Presenilin-1 Allele,”Genesis 26:5-8 (2000).
Zhang, et al., “Presenilins are Required for γ-Secretase Cleavage of β-APP and Transmembrane Cleavage of Notch-1,”Nature Cell Biol. 2:463-465 (2000).
Falk Anne-Marie
Law Office of Michael A. Sanzo, LLC
Sanzo Michael A.
The Brigham and Women's Hospital, Inc.
LandOfFree
Presenilin-deficient mouse model of age-dependent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Presenilin-deficient mouse model of age-dependent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Presenilin-deficient mouse model of age-dependent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3722412